1Clinical Research Coordinating Center, Catholic Medical Center, The Catholic University of Korea, Seoul, Korea
2Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Endocrinology and Metabolism, College of Medicine, The Catholic University of Korea, Seoul, Korea
Copyright © 2020 Korean Society of Cardiovascular Disease Prevention; Korean Society of Cardiovascular Pharmacotherapy.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflict of Interest
The author has no financial conflicts of interest.
Author Contributions
Conceptualization: Lee H, Kim HS; Formal analysis: Kim HS; Methodology: Lee H; Supervision: Kim HS; Writing - original draft: Lee H, Kim HS; Writing - review & editing: Lee H, Kim HS.
Exposed | Disease |
|
---|---|---|
Yes | No | |
Yes | A | B |
No | C | D |
Predicted | Observed |
|
---|---|---|
Yes | No | |
Yes | A | B |
No | C | D |
Assumptions |
---|
1. Assumption of linearity: the relationship between mean value of outcome variable and independent variable is linear. |
2. Assumptions of normality: normality means that the test is normally distributed (or bell-shaped) with 0 mean, 1 standard deviation, and a symmetric bell-shaped curve. |
3. Assumption of homoscedasticity: homoscedasticity means the error term (or residuals) is the same across all values of the independent variables. |